Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia; and Medical School, University of Western Australia, Perth, WA, Australia; and Department of Infectious Diseases, Fiona Stanley Hospital, Perth, WA, Australia.
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia; and Medical School, University of Western Australia, Perth, WA, Australia; and Clinical Pharmacology and Toxicology Unit, PathWest, WA, Australia.
Sex Health. 2024 Mar;21. doi: 10.1071/SH24003.
Syphilis is an important global health threat and little has changed in its treatment since the mid-20th century. For late-latent or syphilis infection of unknown duration, the standard treatment of multiple intramuscular injections of benzathine penicillin G (BPG) are associated with significant pain and distress to clients and caregivers, negatively impacting on treatment completion. Based on pharmacokinetic modelling from a Phase I study of subcutaneous infusion of high dose BPG (SCIP), we present its feasibility, safety and tolerability for treatment of syphilis in a single infusion. SCIP leads to more sustained penicillin concentrations above the desired target with less reported pain and reduced clinic visits.
梅毒是一个重要的全球健康威胁，自 20 世纪中期以来，其治疗方法几乎没有改变。对于潜伏后期或梅毒感染时间不明的患者，标准治疗是多次肌肉注射苄星青霉素 G（BPG），这会给患者和护理人员带来明显的疼痛和不适，从而影响治疗的完成。基于皮下输注高剂量 BPG（SCIP）的 I 期研究的药代动力学模型，我们提出了单次输注 SCIP 治疗梅毒的可行性、安全性和耐受性。SCIP 可使青霉素浓度更持续地维持在所需目标以上，报告的疼痛减轻，就诊次数减少。
